Evanthia Roussos Torres, MD, PhD, discusses the next steps and novel therapies currently showing promise in the HER-2 negative breast cancer space.
Evanthia Roussos Torres, MD, PhD
Advertisement
Articles by Evanthia Roussos Torres, MD, PhD
Evanthia Roussos Torres, MD, PhD, discusses the follow-up research related to the phase 1 study of entinostat administered in combination with nivolumab and ipilimumab for the treatment of locally advanced, metastatic, unresectable, or HER2-negative breast cancer.
Evanthia Roussos Torres, MD, PhD, discusses the phase 1 study of the efficacy of entinostat administered in combination with nivolumab and ipilimumab for the treatment of locally advanced, metastatic, unresectable, or HER2-negative breast cancer.
Advertisement
Latest Updated Articles
What’s Next for the HER2-Negative Breast Cancer Space?August 11th 2022
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC
4
Sofetabart Mipitecan Elicits Responses Across FRα Levels in Ovarian Cancer
5